Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
ProQR Therapeutics N.V. - Ordinary Shares
(NQ:
PRQR
)
2.220
+0.010 (+0.45%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 7, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
526,702
Open
2.150
Bid (Size)
2.210 (2,500)
Ask (Size)
2.740 (1,500)
Prev. Close
2.210
Today's Range
1.970 - 2.220
52wk Range
1.070 - 4.210
Shares Outstanding
80,817,079
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
ProQR Announces Third Quarter 2025 Operating and Financial Results
November 06, 2025
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR Receives CTA Authorization for AX-0810 and Announces Virtual Investor and Analyst Event on November 3, 2025
October 20, 2025
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
Performance
YTD
-19.0%
-19.0%
1 Month
-5.9%
-5.9%
3 Month
+2.3%
+2.3%
6 Month
+37.9%
+37.9%
1 Year
-37.8%
-37.8%
More News
Read More
Curious about the stocks that are showing activity after the closing bell on Thursday?
October 16, 2025
Via
Chartmill
ProQR to Participate in Upcoming Investor Conferences in October 2025
October 13, 2025
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
September 16, 2025
Via
Benzinga
ProQR Announces Second Quarter 2025 Operating and Financial Results
August 07, 2025
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR Announces Upcoming Presentation at RNA Editing Summit
July 28, 2025
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP
June 26, 2025
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences
May 12, 2025
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR Announces First Quarter 2025 Operating and Financial Results
May 08, 2025
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference
May 02, 2025
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025
May 01, 2025
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth
April 14, 2025
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR Announces Year End 2024 Operating and Financial Results
March 13, 2025
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
This Ralph Lauren Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
February 12, 2025
Via
Benzinga
ProQR Therapeutics Announces $8.1 Million in New Funding from Rett Syndrome Research Trust to Expand RNA Editing Collaboration
December 11, 2024
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist
December 10, 2024
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR Therapeutics to Host Virtual Analyst and Investor Event on December 11, 2024
December 05, 2024
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
Neurogene, Nvidia And Other Big Stocks Moving Lower In Monday's Pre-Market Session
November 18, 2024
Via
Benzinga
ProQR Announces Third Quarter 2024 Operating and Financial Results
November 07, 2024
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
This First Solar Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
October 29, 2024
Via
Benzinga
ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement
October 25, 2024
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement
October 22, 2024
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares
October 22, 2024
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
CSX Posts Weak Earnings, Joins Lucid Group, Nokia And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
October 17, 2024
Via
Benzinga
Frequently Asked Questions
Is ProQR Therapeutics N.V. - Ordinary Shares publicly traded?
Yes, ProQR Therapeutics N.V. - Ordinary Shares is publicly traded.
What exchange does ProQR Therapeutics N.V. - Ordinary Shares trade on?
ProQR Therapeutics N.V. - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for ProQR Therapeutics N.V. - Ordinary Shares?
The ticker symbol for ProQR Therapeutics N.V. - Ordinary Shares is PRQR on the Nasdaq Stock Market
What is the current price of ProQR Therapeutics N.V. - Ordinary Shares?
The current price of ProQR Therapeutics N.V. - Ordinary Shares is 2.220
When was ProQR Therapeutics N.V. - Ordinary Shares last traded?
The last trade of ProQR Therapeutics N.V. - Ordinary Shares was at 11/07/25 04:00 PM ET
What is the market capitalization of ProQR Therapeutics N.V. - Ordinary Shares?
The market capitalization of ProQR Therapeutics N.V. - Ordinary Shares is 179.41M
How many shares of ProQR Therapeutics N.V. - Ordinary Shares are outstanding?
ProQR Therapeutics N.V. - Ordinary Shares has 179M shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.